

Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

---

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

Trade name : Etoricoxib Formulation

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

215-631-6999

---

## SECTION 2: Hazards identification



### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 2	H411: Toxic to aquatic life with long lasting effects.

### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :  

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.  
H373 May cause damage to organs through prolonged or repeated exposure.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.

## Etoricoxib Formulation

Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

P260 Do not breathe dust.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P391 Collect spillage.

Hazardous components which must be listed on the label:

Etoricoxib

**Additional Labelling**

EUH212 Warning! Hazardous respirable dust may be formed when used. Do not breathe dust.

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Etoricoxib	202409-33-4	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 2; H373 (Kidney, Liver, Gastrointestinal tract) Aquatic Chronic 2; H411	>= 25 - < 30

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures****4.1 Description of first aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

Version	Revision Date:	SDS Number:	Date of last issue: 02.10.2020
4.0	09.04.2021	26560-00020	Date of first issue: 29.10.2014

---

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : Suspected of damaging the unborn child.  
May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

---

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

#### 5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)

## Etoricoxib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 02.10.2020
4.0	09.04.2021	26560-00020	Date of first issue: 29.10.2014

---

Sulphur oxides  
Chlorine compounds  
Metal oxides  
Oxides of phosphorus

**5.3 Advice for firefighters**

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
- 

**SECTION 6: Accidental release measures****6.1 Personal precautions, protective equipment and emergency procedures**

- Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and material for containment and cleaning up**

- Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

---

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

## Etoricoxib Formulation

Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

**7.2 Conditions for safe storage, including any incompatibilities**

- Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
- Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents

**7.3 Specific end use(s)**

- Specific use(s) : No data available

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	TWA OEL-RL (Respirable dust)	5 mg/m <sup>3</sup>	ZA OEL
		Further information: Recommended Limit		
		TWA OEL-RL (inhalable dust)	10 mg/m <sup>3</sup>	ZA OEL
		Further information: Recommended Limit		
		STEL OEL-RL (Dust)	20 mg/m <sup>3</sup>	ZA OEL
		Further information: Recommended Limit		
Etoricoxib	202409-33-4	TWA	400 ug/m <sup>3</sup> (OEB 2)	Internal
Titanium dioxide	13463-67-7	TWA OEL-RL	5 mg/m <sup>3</sup>	ZA OEL

# SAFETY DATA SHEET



## Etoricoxib Formulation



Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

	(Respirable dust)	
Further information: Recommended Limit		
	TWA OEL-RL (inhalable dust)	10 mg/m <sup>3</sup> ZA OEL
Further information: Recommended Limit		

### 8.2 Exposure controls

#### Engineering measures

Ensure adequate ventilation, especially in confined areas.  
Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

#### Personal protective equipment

- Eye protection : Wear the following personal protective equipment:  
Safety goggles
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
- Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.  
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type (P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

- Appearance : powder  
Colour : coloured  
Odour : odourless  
Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling : No data available

# SAFETY DATA SHEET



## Etoricoxib Formulation



Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

---

range	
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids)	: No data available
Molecular weight	: No data available
Particle size	: No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means.
---------------------	---

# SAFETY DATA SHEET



## Etoricoxib Formulation



Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

---

Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

#### Components:

##### **Etoricoxib:**

Acute oral toxicity : LD50 (Rat): 1.499 mg/kg  
LD50 (Mouse): 1.499 mg/kg  
Acute toxicity (other routes of administration) : LD50 (Rat): 238 mg/kg  
Application Route: Intraperitoneal  
LD50 (Mouse): 599 mg/kg  
Application Route: Intraperitoneal

#### **Skin corrosion/irritation**

Not classified based on available information.

#### Components:

##### **Etoricoxib:**

Species : Rabbit  
Result : No skin irritation

#### **Serious eye damage/eye irritation**

Not classified based on available information.



## Etoricoxib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 02.10.2020
4.0	09.04.2021	26560-00020	Date of first issue: 29.10.2014

---

**Components:****Etoricoxib:**

Species	: Rabbit
Result	: Mild eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Etoricoxib:**

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Assessment	: Did not cause sensitisation on laboratory animals.
Result	: negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Etoricoxib:**

Genotoxicity in vitro	: Test Type: reverse mutation assay
	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Test system: human lymphoblastoid cells
	Result: negative
	Test Type: Chromosomal aberration
	Test system: Chinese hamster ovary cells
	Result: negative
	Test Type: Alkaline elution assay
	Result: negative
Genotoxicity in vivo	: Test Type: Chromosomal aberration
	Species: Rat
	Cell type: Bone marrow
	Application Route: Oral
	Result: negative
	Test Type: Alkaline elution assay
	Species: Rat
	Application Route: Oral
	Result: negative

## Etoricoxib Formulation

Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

---

**Carcinogenicity**

Not classified based on available information.

**Components:****Etoricoxib:**

Species : Rat, male and female  
Application Route : oral (gavage)  
Exposure time : 2 Years  
Result : positive

Species : Mouse, male and female  
Application Route : oral (gavage)  
Exposure time : 2 Years  
Result : negative

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****Etoricoxib:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, female  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 10 mg/kg body weight  
Result: positive

Test Type: Fertility/early embryonic development  
Species: Rat, male  
Application Route: Oral  
Result: negative

Effects on foetal development : Species: Rat  
Application Route: Oral  
Result: positive

Species: Rabbit  
Application Route: Oral  
Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:****Etoricoxib:**

Exposure routes : Ingestion  
Target Organs : Kidney, Liver, Gastrointestinal tract

## Etoricoxib Formulation

Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Etoricoxib:**

Species : Rat  
LOAEL : 30 mg/kg  
Application Route : oral (gavage)  
Exposure time : 27 Weeks  
Target Organs : Gastrointestinal tract, Kidney

Species : Rat  
NOAEL : 30 mg/kg  
Application Route : oral (gavage)  
Exposure time : 53 Weeks  
Target Organs : Liver

Species : Dog  
NOAEL : 50 mg/kg  
Application Route : oral (gavage)  
Exposure time : 53 Weeks  
Target Organs : Liver

Species : Dog  
LOAEL : 200 mg/kg  
Application Route : oral (gavage)  
Exposure time : 14 Weeks  
Target Organs : Gastrointestinal tract, Kidney

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Etoricoxib:**

Ingestion : Symptoms: upper respiratory tract infection, Headache, hypertension, Diarrhoea, urinary tract infection, flu-like symptoms, heartburn, Nausea, bronchitis, Dizziness, asthenia, Rash, Back pain, Cough, Abdominal pain, pharyngitis, Oedema

**SECTION 12: Ecological information****12.1 Toxicity****Components:****Etoricoxib:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 30 mg/l  
Exposure time: 96 h

# SAFETY DATA SHEET



## Etoricoxib Formulation



Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

		Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 30 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC : 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	:	NOEC: 7,93 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 0,75 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

### 12.2 Persistence and degradability

#### Components:

##### **Etoricoxib:**

Biodegradability : Result: not rapidly degradable  
Biodegradation: 0,2 %  
Exposure time: 28 d

### 12.3 Bioaccumulative potential

#### Components:

##### **Etoricoxib:**

Partition coefficient: n-octanol/water : log Pow: 2,3

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered

Version	Revision Date:	SDS Number:	Date of last issue: 02.10.2020
4.0	09.04.2021	26560-00020	Date of first issue: 29.10.2014



to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

**Product:**

Endocrine disrupting potential	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
--------------------------------	---	---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number

ADN	:	UN 3077
ADR	:	UN 3077
RID	:	UN 3077
IMDG	:	UN 3077
IATA	:	UN 3077

### 14.2 UN proper shipping name

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Etoricoxib)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Etoricoxib)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Etoricoxib)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Etoricoxib)

## Etoricoxib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 02.10.2020
4.0	09.04.2021	26560-00020	Date of first issue: 29.10.2014

---

**IATA** : Environmentally hazardous substance, solid, n.o.s.  
(Etoricoxib)

**14.3 Transport hazard class(es)**

**ADN** : 9  
**ADR** : 9  
**RID** : 9  
**IMDG** : 9  
**IATA** : 9

**14.4 Packing group**

**ADN**  
Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9

**ADR**  
Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

**RID**  
Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9

**IMDG**  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

**IATA (Cargo)**  
Packing instruction (cargo aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

**IATA (Passenger)**  
Packing instruction (passenger aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

**14.5 Environmental hazards**

**ADN**  
Environmentally hazardous : yes

**ADR**  
Environmentally hazardous : yes

# SAFETY DATA SHEET



## Etoricoxib Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 02.10.2020
4.0	09.04.2021	26560-00020	Date of first issue: 29.10.2014

---

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302 : Harmful if swallowed.

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

H411 : Toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ZA OEL : South Africa. Hazardous Chemical Substances Regulations,

# SAFETY DATA SHEET



## Etoricoxib Formulation



Version 4.0      Revision Date: 09.04.2021      SDS Number: 26560-00020      Date of last issue: 02.10.2020  
Date of first issue: 29.10.2014

### Occupational Exposure Limits

ZA OEL / TWA OEL-RL : Long term occupational exposure limits - recommended limit  
ZA OEL / STEL OEL-RL : Short term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Repr. 2                      H361d  
STOT RE 2                      H373  
Aquatic Chronic 2                      H411

### Classification procedure:

Calculation method  
Calculation method  
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be



# SAFETY DATA SHEET



## Etoricoxib Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 02.10.2020
4.0	09.04.2021	26560-00020	Date of first issue: 29.10.2014

---

considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN